Stock Analysis: Coal India, Dr Reddy's Laboratories

Read this in-depth analysis if you hold or plan to buy these scrips anytime soon.

Coal India’s stock, amid volatility, had failed to give positive returns during 2011-12 and underperformed till mid-May this year. However, some positive triggers such as good monthly production and sales numbers for April and May have provided confidence on the ability to deliver a healthy increase of five to seven per cent in output in 2012-13. This, in turn, has eased concerns on reduction in higher priced e-auction quantities and non-priority sectors. Click here for more

Dr Reddy’s Laboratories’ scrip has been down about eight per cent over the last month on weak results, underperforming its peer index, which has been flat, and the broader Sensex, which has gained 3.5 per cent. While this fall is part of the stock’s underperformance starting April this year, partly on account of investors moving away from defensives to riskier assets as well as some profit booking, news flow for the company has been positive in the last week. More importantly, the future prospects remain robust and stock valuations at current levels of Rs 1,573 are attractive. Click here for more